CVI42 vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CVI42

by CIRCLE CARDIOVASCULAR IMAGING

EchoNext

by Pathway Labs

AI Verdict

CVI42 is an AI-enabled software platform for comprehensive cardiac and vascular *imaging analysis*, utilizing CT and MRI tools for diagnosis, planning, and patient care. EchoNext, on the other hand, is an AI tool that analyzes standard *ECGs* to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, acting as a screening tool to identify patients who should proceed to an echocardiogram. While both tools focus on cardiology and leverage AI, their distinct input data (imaging vs. ECG) and primary function (detailed analysis vs. screening) make them adjacent rather than direct competitors.

Choose CVI42 if…

Choose CVI42 if your institution requires a comprehensive, AI-enabled platform for advanced cardiac and vascular imaging analysis using both CT and MRI. It is ideal for cardiologists and radiologists who need detailed plaque analysis, advanced CMR automation (like T1 mapping and 4D flow pre-processing), and vascular CT analysis for diagnosis, planning, and post-treatment surveillance, all within a unified workflow. This tool is particularly well-suited for centers aiming to integrate anatomy, function, and inflammation assessment for a holistic view of patient health.

View CVI42 →

Choose EchoNext if…

Choose EchoNext if your primary need is an accessible, non-invasive AI tool for early detection and screening of hidden structural heart disease from standard 12-lead ECGs. This is particularly beneficial for broad access screening in various clinical settings, from major hospitals to community practices, to identify patients at risk for conditions like heart failure, valve disease, and pulmonary hypertension who may require further echocardiographic evaluation. It is designed to bridge the gap in early structural heart disease detection, especially where echocardiography access might be limited.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CVI42	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	On-premise solution	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CVI42

CVI42 emphasizes an intuitive user experience with streamlined workflows for both CT and CMR studies, aiming to reduce reporting times and clerical workload. EchoNext, while integrated into the OpenEvidence platform, focuses more on its diagnostic capabilities rather than specific user interface benefits. CVI42 also offers multi-language support and flexible deployment options (standalone or client/server), further enhancing its usability in diverse clinical settings.

Clinical Value

EchoNext

EchoNext has demonstrated superior clinical value by accurately identifying structural heart disease from ECGs, outperforming cardiologists in studies. It has received FDA clearance for six indications, including heart failure, valve disease, and pulmonary hypertension, and has been credited with detecting undiagnosed heart failure that led to a heart transplant. CVI42 offers comprehensive cardiac and vascular imaging analysis with AI-automated segmentation and plaque analysis, which is valuable for diagnosis and planning, but EchoNext's ability to detect hidden structural heart disease from a routine, inexpensive test like an ECG represents a significant advancement in early detection and patient care.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with discounts for annual commitments and clear details on implementation fees. CVI42 requires contacting for pricing, with estimates ranging from $5,000 for a single user perpetual license to over $250,000 for a large enterprise, plus variable implementation and maintenance costs. EchoNext's clear pricing structure and lower entry point likely offer better value for a broader range of practices, especially smaller ones or those looking for a more predictable cost model.

Enterprise Readiness

CVI42

CVI42 is designed for enterprise environments, supporting both standalone and client/server deployments with full DICOM connectivity to PACS and HL7 compatibility. It also offers advanced enterprise security features like Single Sign-on (SSO) and Multi-factor Authentication (MFA). EchoNext is available through the OpenEvidence platform and is designed for broad access, but CVI42's detailed specifications for network deployment, data security (local processing), and integration capabilities suggest a more robust enterprise-grade solution.

Innovation

EchoNext

EchoNext represents a significant innovation as the world's first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a widely available and inexpensive test. This capability addresses a critical gap in early detection for cardiovascular disease. While CVI42 offers advanced AI for cardiac imaging analysis and continuous improvements, EchoNext's novel approach to leveraging ECG data for broad-scale screening is a more groundbreaking innovation in the field.

Support & Docs

CVI42

CVI42 explicitly states it offers world-class support and clinical teams, global support in multiple languages and time zones, and provides extensive documentation and archived tutorials. EchoNext's documentation and support details are not as extensively highlighted in the provided information, making CVI42 the stronger contender in this dimension due to its explicit commitment to comprehensive support and resources.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CVI42	EchoNext
Name	CVI42	EchoNext
Company	CIRCLE CARDIOVASCULAR IMAGING	Pathway Labs
Description	CVI42 is an AI-enabled software platform by Circle Cardiovascular Imaging for comprehensive cardiac and vascular imaging analysis, enhancing diagnosis, planning, and patient care with advanced CT and MRI tools.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	AI-automated coronary lumen and wall segmentation, Comprehensive coronary plaque analysis (calcified, non-calcified, low-attenuation), Advanced CMR automation (T1 mapping, 4D flow pre-processing), Vascular CT analysis and planning tools, Automated detection of suspected coronary lesions, Pericoronary Adipose Tissue (PCAT) analysis (research use only), 3D visualization and image fusion, Automated contouring of regions of interest	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring CVI42 and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing cardiology workflows and EHR systems, and what is the depth of data exchange?

CVI42 is an on-premise solution for comprehensive cardiac and vascular imaging analysis, suggesting a direct integration with imaging PACS and potentially requiring custom EHR interfaces for data exchange. EchoNext is available through the OpenEvidence clinical decision support platform, implying integration within that platform's existing EHR connections for ECG data analysis and result reporting.

What is the primary clinical application and target patient population for each tool, and how do they differ in their diagnostic approach?

CVI42 focuses on advanced analysis of cardiac and vascular CT/MRI images for diagnosis, planning, and patient care, suitable for patients undergoing detailed imaging studies. EchoNext analyzes standard 12-lead ECGs to detect hidden structural heart disease (heart failure, valve disease, pulmonary hypertension), making it a screening tool for a broader patient population, potentially even in primary care settings.

What is the learning curve for physicians and technologists to effectively use each tool, and what kind of support is provided during and after implementation?

CVI42, with its advanced imaging analysis features and specialized modules, may involve a steeper learning curve for users to master its full capabilities, likely supported by specialized training from Circle Cardiovascular Imaging. EchoNext, analyzing standard ECGs through a clinical decision support platform, might have a more intuitive interface for physicians, with support likely provided by Pathway Labs or the OpenEvidence platform.

Beyond HIPAA, what specific security measures and audit trail features are in place to protect patient data and ensure diagnostic integrity?

CVI42, as an on-premise solution, would likely rely on the institution's existing IT security infrastructure, with specific audit trail features for image analysis actions. EchoNext, operating within the OpenEvidence platform, would leverage that platform's security framework and likely offer audit trails for ECG analysis requests and results, though specific details beyond HIPAA are not provided for either.

How do these tools support multi-site or large-scale hospital system rollouts, particularly concerning data management and standardization?

CVI42, being an on-premise solution, would require individual deployments and potentially centralized data management strategies for each site, ensuring standardization across multiple locations. EchoNext, delivered via a clinical decision support platform, could potentially offer a more streamlined rollout across multiple sites by leveraging the platform's existing infrastructure and standardized data handling.

Can physicians access customer references or case studies to understand real-world implementation and clinical impact for each tool?

The provided information does not explicitly state the availability of customer references or case studies for either CVI42 or EchoNext. Physicians would need to contact Circle Cardiovascular Imaging and Pathway Labs directly to inquire about such resources to evaluate real-world performance and clinical utility.